Update Breast Cancer 2023 Part 1 – Early Stage Breast Cancer

With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartkopf, Andreas D., Fehm, Tanja N., Welslau, Manfred, Müller, Volkmar, Schütz, Florian, Fasching, Peter A., Janni, Wolfgang, Witzel, Isabell, Thomssen, Christoph, Beierlein, Milena, Belleville, Erik, Untch, Michael, Thill, Marc, Tesch, Hans, Ditsch, Nina, Lux, Michael P., Aktas, Bahriye, Banys-Paluchowski, Maggie, Kolberg-Liedtke, Cornelia, Wöckel, Achim, Kolberg, Hans-Christian, Harbeck, Nadia, Stickeler, Elmar, Bartsch, Rupert, Schneeweiss, Andreas, Ettl, Johannes, Würstlein, Rachel, Krug, David, Taran, Florin-Andrei, Lüftner, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10617391/
https://www.ncbi.nlm.nih.gov/pubmed/37916183
http://dx.doi.org/10.1055/a-2074-0551
Descripción
Sumario:With abemaciclib (monarchE study) and olaparib (OlympiA study) gaining approval in the adjuvant treatment setting, a significant change in the standard of care for patients with early stage breast cancer has been established for some time now. Accordingly, some diverse developments are slowly being transferred from the metastatic to the adjuvant treatment setting. Recently, there have also been positive reports of the NATALEE study. Other clinical studies are currently investigating substances that are already established in the metastatic setting. These include, for example, the DESTINY Breast05 study with trastuzumab deruxtecan and the SASCIA study with sacituzumab govitecan. In this review paper, we summarize and place in context the latest developments over the past months.

Ejemplares similares